Clostridial necrotizing enteritis

Latest Updates of Viva's Portfolio Companies

Retrieved on: 
Monday, December 4, 2023
JAK1, NMPA, Patient, American College of Rheumatology, Bayer, SUA, Neoplasm, Cataract, Therapy, URAT1, MBA, Cancer, Health care, Inflammation, Fabry disease, Safety, Toxicity, IND, SHP2, USD, Strong, Letter, Woman, EA Phenomic, Pharmacokinetics, VBI, HER2, MPM, Antibody, GCS, GEJ, Boehringer, Research, Plasma, Boehringer Ingelheim, Clinical trial, Investment, MaRS Discovery District, FDA, American College, Phase II, Clostridial necrotizing enteritis, Selective, MPH, ACR, EGFR, Pharmaceutical industry, Astellas Pharma, Phase, Deka, Facet joint arthrosis

TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--On Nov. 29th, Phenomic AI ("Phenomic"), invested and incubated by Viva BioInnovator (VBI), announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers. The partners will leverage Phenomic's expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer's efforts to develop first-in-class medicines to transform the lives of people with cancer by delivering meaningful advances with the ultimate goal to cure a range of cancers. Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones. Phenomic is also eligible to receive more than USD $500 million in licensing fees as well as clinical, regulatory and commercial milestones in addition to royalties on future product sales.

Key Points: 
  • HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development.
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva's portfolio companies have new updates.
  • Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones.

First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

Retrieved on: 
Wednesday, September 7, 2022
FW, CEO, Research, Stomach, Cystic Fibrosis Foundation, Niclosamide, Nutrient, Steatorrhea, Fats, Clostridial necrotizing enteritis, U.S. Securities and Exchange Commission, CDMO, GMP, BOCA, GLOBE, Company, Patient, CP, Exocrine pancreatic insufficiency, CTM, Yarrowia, Hope, First wave, CMC, Cystic fibrosis, List of life sciences, EPI, FDA, Weight loss, Ulcerative colitis, Capsule, Trial of the century, Investigational New Drug, Security (finance), Food, Diarrhea, NASDAQ, AAPS, GI, Duodenum, PERT, Acquisition, CF, IND, CFA, Technology company, Clinical trial, Digestion, Pharmaceutical industry

BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the selection of an enhanced enteric microgranule drug delivery formulation for the ongoing development of its adrulipase clinical program (FW-EPI). First Wave BioPharma now plans to submit an Investigational New Drug (IND) amendment to the U.S. Food & Drug Administration (FDA) for a Phase 2 “proof-of-concept” clinical study investigating the optimized version of adrulipase as a treatment for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP). First Wave BioPharma expects to initiate the Phase 2 trial prior to year-end 2022 following acceptance of the IND.

Key Points: 
  • BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, announced today the selection of an enhanced enteric microgranule drug delivery formulation for the ongoing development of its adrulipase clinical program (FW-EPI).
  • First Wave BioPharma expects to initiate the Phase 2 trial prior to year-end 2022 following acceptance of the IND.
  • The selection of the enteric microgranule drug delivery technology follows extensive research by First Wave BioPharma and our drug delivery formulation partner, Pace Life Sciences, into the development and manufacturing of the optimized adrulipase formulation, said James Sapirstein, President and CEO of First Wave BioPharma.
  • Additionally, First Wave BioPharma previously published a white paper detailing the development of the microgranule formulation for adrulipase.

First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract

Retrieved on: 
Wednesday, August 31, 2022
CF, Security (finance), FW, CEO, Technology, Diarrhea, Research, CP, Exocrine pancreatic insufficiency, NASDAQ, Cystic Fibrosis Foundation, AAPS, Niclosamide, Yarrowia, Nutrient, First wave, Fats, Science, Cystic fibrosis, Clostridial necrotizing enteritis, U.S. Securities and Exchange Commission, Boston Convention and Exhibition Center, List of life sciences, GMP, EPI, Digestion, BOCA, GLOBE, CDMO, Company, Weight loss, Clinical trial, Ulcerative colitis, Acquisition, Capsule, Patient, CRO, Pharmaceutical industry

BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, announced today that an abstract titled, Formulation Development of Enterically Protected Spray Dried Dispersions of Adrulipase, has been accepted at AAPS 2022 PharmSci 360 .

Key Points: 
  • BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (First Wave BioPharma or the Company), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies forgastrointestinal (GI) diseases, announced today that an abstract titled, Formulation Development of Enterically Protected Spray Dried Dispersions of Adrulipase, has been accepted at AAPS 2022 PharmSci 360 .
  • We are very pleased that First Wave and Paces research into the development of a microgranule delivery formulation for adrulipase was accepted for presentation at the AAPS 2022 PharmSci 360 conference, said James Sapirstein, President and CEO of First Wave BioPharma.
  • We are excited to report that an optimal microgranule formulation has been developed, and we now look forward to initiating a clinical trial utilizing this formulation this year.
  • First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

Amlan to Feature New Product, Phylox® and Share Recent Commercial Varium® Research at XLVI ANECA 2022 Annual Congress

Retrieved on: 
Tuesday, March 15, 2022
Program, Solution, Clostridium perfringens, UNAM, GLOBE, Ionophore, Health, ODC, National Association, XLVI, Government, Clostridial necrotizing enteritis, Transport, ANECA, Economics, Poultry, Marketing, Research, Congress, Bird, NYSE, Industry, Poultry Science Association, Salmonella, Culture, New, VP, Feed manufacturing, Coccidiosis, Eimeria

The active ingredients in Phylox have been demonstrated through independent research to interrupt the life cycle of various Eimeria species, the causative agents in coccidiosis.

Key Points: 
  • The active ingredients in Phylox have been demonstrated through independent research to interrupt the life cycle of various Eimeria species, the causative agents in coccidiosis.
  • The synergistic blend of bioactive phytochemicals in Phylox also helps strengthen bird intestinal integrity and supports strong, natural immune function.
  • Amlan is taking part in multiple events throughout the ANECA congress including hosting a presentation at 9 a.m. on Thursday, March 31, byDr.
  • Further details about the XLVI ANECA 2022 Annual Congress can be found here .